Cannabis Trends to Watch

The cannabis industry is not moving in one straight line. Some parts of the market are becoming more regulated, more professional, and more science-driven. Other parts remain fragmented by state laws, federal uncertainty, product safety concerns, and uneven access to banking, research, and capital.

That mix is what makes the next decade important. The future of cannabis will not be shaped by one single breakthrough. It will likely come from several overlapping shifts: federal scheduling decisions, medical research, minor cannabinoid innovation, more sophisticated product formats, and pressure to grow cannabis with a smaller environmental footprint.

For consumers, that means more choices, but also more need to understand labels, potency, product type, and regulation. For businesses, it means opportunity will increasingly depend on compliance, consumer trust, and the ability to adapt as rules change.

Federal cannabis policy is changing, but not becoming simple

Federal policy remains one of the biggest forces shaping the future of cannabis in the United States. In 2024, the Department of Justice proposed moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. In April 2026, the Justice Department announced a narrower Schedule III action for certain FDA-approved cannabis products and products tied to qualifying state-issued medical licenses, while also moving toward a broader administrative process for complete redesignation.

That matters, but it is not the same thing as federal legalization. Even if broader Schedule III redesignation is finalized, cannabis would still remain federally regulated. Schedule III status could change tax treatment, research pathways, and medical framing, but it would not automatically make adult-use cannabis legal nationwide or erase the gap between state-legal markets and federal law.

Banking reform is another key pressure point. Many cannabis businesses still face limited access to ordinary financial services because cannabis activity can remain legally complicated under federal law. That affects payment processing, lending, insurance, payroll, security, and long-term investment. Federal banking reform could make the industry more stable, but operators should not assume it will arrive on a predictable timeline.

The practical takeaway: policy change will likely continue in stages. Businesses should prepare for more federal involvement, not fewer rules. Consumers should expect state-by-state differences to remain important.

Medical cannabis research will grow, but careful language still matters

Medical cannabis research is expanding, especially around chronic pain, cannabinoid ratios, product formats, and adverse effects. The strongest public conversation often centers on whether cannabis can help with pain, sleep, anxiety, inflammation, or neurological symptoms. The research picture is more nuanced than the marketing language often suggests.

A 2025 living systematic review from the Agency for Healthcare Research and Quality updated evidence on cannabinoids and other plant-based treatments for chronic and subacute pain. The review grouped products by THC-to-CBD ratio and product type, which reflects a bigger shift in cannabis science: researchers are not just asking whether “cannabis works.” They are asking which compounds, formats, ratios, and patient populations may matter.

That distinction is important. A high-THC edible, a balanced THC:CBD tincture, an FDA-approved cannabinoid medication, and a topical CBD product are not interchangeable. They may have different effects, risks, onset times, and evidence levels. As the research matures, expect more attention to product-specific evidence rather than broad claims about cannabis as a category.

For consumers, the future of medical cannabis will likely involve more detailed conversations with clinicians, pharmacists, and dispensary staff. For businesses, vague wellness claims will become riskier as regulators and consumers expect better evidence. Products that can clearly explain potency, ingredients, intended use, testing, and limitations will have an advantage.

Minor cannabinoids will move from novelty to product strategy

THC and CBD will remain central, but minor cannabinoids are already becoming a larger part of product development. CBG, CBN, THCV, CBC, and other cannabinoids are showing up in tinctures, gummies, beverages, capsules, vapes, and topicals. Some are marketed for focus, sleep, appetite, recovery, or calm.

The opportunity is real, but so is the need for caution. Many minor cannabinoids have less human clinical research behind them than THC or CBD. Consumer-reported effects can be useful for product positioning, but they should not be treated as medical proof. A product label that says “CBN for sleep” or “THCV for focus” may reflect a market trend more than a settled scientific conclusion.

The bigger trend is formulation. Brands are trying to design experiences instead of selling cannabis only by THC percentage. That could mean lower-dose edibles with balanced cannabinoid ratios, beverages designed for social occasions, or non-intoxicating products for consumers who want cannabis-adjacent wellness without euphoria.

This shift may be good for consumers when it comes with clear labeling and contaminant testing. It becomes risky when products make unsupported health claims, hide intoxicating effects behind “hemp” language, or mimic ordinary snacks. Regulators have already paid attention to intoxicating hemp-derived products and copycat packaging, especially where children or pets could be exposed.

Wellness products will keep expanding, but trust will separate strong brands from weak ones

Cannabis-infused wellness products will likely keep growing across categories such as beverages, topicals, skincare, low-dose edibles, tinctures, and functional formats. This part of the market appeals to consumers who are not necessarily looking for strong intoxicating effects. They may want relaxation, a social alcohol alternative, post-workout comfort, or a topical product that fits into an existing self-care routine.

The challenge is that “wellness” can become vague quickly. CBD is widely marketed, but the FDA has said existing food and dietary supplement frameworks are not appropriate for CBD and has continued to monitor cannabis-derived products. That means brands need to be careful about how they describe products, especially when making claims about health conditions.

The next decade will likely reward brands that are boring in the best way: clear serving sizes, transparent cannabinoid content, accessible certificates of analysis, realistic language, and packaging that does not appeal to children. Trust will matter more as consumers learn the difference between regulated cannabis products, hemp-derived intoxicating products, and general wellness products that happen to include cannabinoids.

For consumers, the best habit is to compare products by more than the front label. Look for the cannabinoid profile, serving size, total package potency, ingredient list, test results, and whether the product is sold through a regulated channel. For businesses, education will be part of the product. A confusing product may sell once. A clear product can build loyalty.

Sustainability will become a business issue, not just a values issue

Cannabis cultivation can be resource-intensive, especially in indoor facilities that rely on lighting, HVAC systems, dehumidification, water management, and controlled environments. Sustainability is already becoming part of the industry conversation because energy use affects operating costs, local infrastructure, carbon emissions, and brand reputation.

Recent life-cycle research has highlighted the climate impact of energy-intensive indoor cultivation and suggested that outdoor cultivation can reduce emissions significantly in some contexts. That does not mean outdoor cultivation is always the right answer. Climate, security, state rules, quality goals, pest pressure, and supply-chain needs all matter. But it does mean cultivation methods will face more scrutiny.

Sustainable cannabis production is not just about solar panels or “organic” language. It can include efficient lighting, water recapture, integrated pest management, renewable energy procurement, packaging reduction, composting plant waste where allowed, and better facility design. For retailers and consumers, it may also mean asking how a product was grown, not only how potent it is.

Over the next decade, sustainability could become a competitive advantage. Operators that reduce energy waste may lower costs. Brands that can document environmental improvements may stand out. Regulators may also put more pressure on cultivation energy use, especially in markets where indoor production strains local grids.

What cannabis businesses should watch next

The cannabis businesses most likely to adapt will be the ones that treat uncertainty as part of the operating environment. Federal reform, state rule changes, product safety enforcement, cannabinoid innovation, and consumer education will keep moving at different speeds.

Key areas to watch include:

• Federal scheduling and whether broader redesignation is finalized.
• Banking access and financial compliance expectations.
• FDA and FTC activity around cannabis-derived products, CBD, intoxicating hemp products, and copycat packaging.
• State-level rules for hemp-derived intoxicating cannabinoids.
• Research on specific cannabinoid ratios, product formats, and health outcomes.
• Energy, water, packaging, and waste requirements for cultivation and manufacturing.
• Consumer demand for lower-dose, non-intoxicating, and precisely labeled products.

The next decade will not simply be about bigger sales. It will be about credibility. The cannabis industry is moving from early-market excitement toward a more demanding phase where claims, labels, operations, and environmental practices all matter.

Key takeaways

The future of cannabis will be shaped by policy, science, product innovation, and sustainability at the same time. Federal reform may reduce some barriers, but it will not automatically create a simple national market. Medical research will keep expanding, but product-specific evidence will matter more than broad claims. Minor cannabinoids and wellness formats will create new opportunities, but only if brands avoid overpromising.

For consumers, the smartest approach is to stay curious and cautious: read labels, understand potency, ask questions, and pay attention to whether a product is regulated and tested. For businesses, the path forward is clear even when the law is not: build trust, document quality, follow current rules, and prepare for a market where cannabis is judged by more than novelty.

Sources

• Federal Register, “Schedules of Controlled Substances: Rescheduling of Marijuana”
• U.S. Department of Justice, “Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III”
• DEA, “Hearing on the Proposed Rescheduling of Marijuana Postponed”
• FDA, “FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)”
• FDA, “5 Things to Know about Delta-8 Tetrahydrocannabinol”
• AHRQ, “Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update”
• One Earth, “Energy-intensive indoor cultivation drives the cannabis industry’s expanding carbon footprint”

Further Reading

• The Future of Cannabis Banking: Will Federal Reform Solve the Cash Problem?
• The Impact of Federal Legalization on Cannabis Businesses
• The Role of Cannabinoids Beyond THC & CBD: CBN, CBG, and THCV
• Sustainability in the Cannabis Industry: How Businesses Are Going Green
• The Rise of Cannabis Startups: Where the Market is Heading